公开(公告)号：US20230310564A1

公开(公告)日：2023-10-05

申请号：US17912331

申请日：2021-03-19

Applicant: FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA ,  INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS

Inventor： Carlos Piñero Lambea ,  Maria Lluch Senar ,  Luis Serrano Pubul

IPC: A61K39/02 ,  C12N1/20 ,  C12N1/36 ,  C12N15/74 ,  C12N9/04 ,  C12N9/90 ,  C12N9/10 ,  A61P31/04

CPC classification number: A61K39/0241 ,  A61P31/04 ,  C12N1/20 ,  C12N1/36 ,  C12N9/0006 ,  C12N9/1051 ,  C12N9/90 ,  C12N15/74 ,  C12Y101/05003 ,  C12Y501/03002 ,  A61K2039/522 ,  C12N2800/101

Abstract: The present invention concerns genetically modified Mycoplasma bacteria. Also intended are methods of generating attenuated Mycoplasma bacteria and their use to produce heterologous gene products. Further intended are pharmaceutical compositions comprising the attenuated Mycoplasma bacteria described herein.

公开(公告)号：US20230241198A1

公开(公告)日：2023-08-03

申请号：US18003056

申请日：2021-07-22

Applicant: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.

Inventor： Edgar Diaz ,  Greg Stewart Cline ,  Jeremy Kroll ,  Fernando Lopes Leivas Leite ,  Michael B. Roof ,  Mike Alan Steilen

IPC: A61K39/02 ,  A61K39/295 ,  A61K39/39 ,  A61P31/04 ,  A61P31/20

CPC classification number: A61K39/105 ,  A61K39/39 ,  A61K39/0241 ,  A61K39/295 ,  A61P31/04 ,  A61P31/20 ,  A61K2039/70

Abstract: The present invention relates to a vaccine comprising an antigen of Lawsonia intracellularis and one or more antigens of at least one further pathogen selected from the group of porcine circovirus (PCV), Mycoplasma hyopneumoniae (M. hyo.) and porcine respiratory and reproductive syndrome virus (PRRSV), wherein the antigen of Lawsonia intracellularis is live Lawsonia intracellularis.

公开(公告)号：US09878027B2

公开(公告)日：2018-01-30

申请号：US14135791

申请日：2013-12-20

Applicant: Dianna M. Murphy Jordan ,  Brian Thomas Martinson ,  Christine Margaret Muehlenthaler ,  Axel Neubauer ,  Arun V. Iyer

Inventor： Dianna M. Murphy Jordan ,  Brian Thomas Martinson ,  Christine Margaret Muehlenthaler ,  Axel Neubauer ,  Arun V. Iyer

IPC: A61K39/00 ,  A61K39/02 ,  A61K35/22

CPC classification number: A61K39/0241 ,  A61K35/22 ,  A61K2039/70

Abstract: The present invention relates to an immunogenic composition comprising: a) one or more antigen of M. hyorhinis and one or more antigens of M. hyosynoviae; and b) a pharmaceutically acceptable carrier. Furthermore, the present invention relates to an immunogenic composition that comprises a) one or more mycoplasma antigens of mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae; and b) one or more components of a eukaryotic cell system. Moreover, the present invention also provides an immunogenic composition obtained by a method comprising a) cultivation of a mycoplasma bacteria selected from the group consisting of M. hyorhinis, M. hyopneumoniae and M. hyosynoviae in a serum-reduced, eukaryotic cell system; b) obtaining an antigen of such mycoplasma bacteria; and c) addition of a pharmaceutically acceptable carrier.

公开(公告)号：US09775893B2

公开(公告)日：2017-10-03

申请号：US15453691

申请日：2017-03-08

Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTE

Inventor： Jiunn-Horng Lin ,  Jyh-Perng Wang ,  Ming-Wei Hsieh ,  Zeng-Weng Chen ,  Chien-Yu Fang ,  Hsueh-Tao Liu ,  Ping-Cheng Yang

IPC: A61K39/02 ,  A61K39/385 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K39/0241 ,  A61K39/0208 ,  A61K45/06 ,  A61K2039/545 ,  A61K2039/552 ,  A61K2039/55505 ,  C07K14/30 ,  C12N15/70

Abstract: Provided in the present invention are anti-Mycoplasma spp. subunit vaccines, especially proteins suitable for being used as the active ingredient of the Mycoplasma spp. subunit vaccines, and a vaccine prepared therefrom. Upon experimenting, it is confirmed that the proteins can elicit an immune response having sufficient strength to avoid the infection of Mycoplasma spp. in pigs. The vaccine can comprise one of the aforementioned proteins as an active ingredient, or can comprise two or more of the proteins to form a form of cocktail vaccine. The vaccine of the present invention is not only more safe than conventional vaccines, but also has equivalent or even better immune effects.

公开(公告)号：US09730987B2

公开(公告)日：2017-08-15

申请号：US14632863

申请日：2015-02-26

Applicant: MERIAL INC.

Inventor： Noel Joseph Francois Detraz ,  Guillaume Rigaut

IPC: A61K39/00 ,  A61K47/26 ,  A61K9/00 ,  A61K9/107 ,  A61K45/06 ,  A61K47/06 ,  C12N7/00 ,  A61K39/39 ,  A61K39/02 ,  A61K39/12 ,  A61K39/135 ,  A61K39/125

CPC classification number: A61K39/00 ,  A61K9/0019 ,  A61K9/107 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/125 ,  A61K39/135 ,  A61K39/39 ,  A61K45/06 ,  A61K47/06 ,  A61K47/26 ,  A61K2039/52 ,  A61K2039/525 ,  A61K2039/5252 ,  A61K2039/54 ,  A61K2039/552 ,  A61K2039/55505 ,  A61K2039/55566 ,  A61K2039/55577 ,  C12N7/00 ,  C12N2750/00022 ,  C12N2750/00034 ,  C12N2750/10034 ,  C12N2770/32022 ,  C12N2770/32134

Abstract: The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof.

公开(公告)号：US20170209560A1

公开(公告)日：2017-07-27

申请号：US15480949

申请日：2017-04-06

Applicant: Zoetis Services LLC

Inventor： Jeffrey E. Galvin ,  Gregory P. Nitzel ,  John Keith Garrett ,  James R. Kulawik, II ,  Tracy L. Ricker ,  Megan Marie Smutzer

IPC: A61K39/02 ,  A61K39/39

CPC classification number: A61K39/0241 ,  A61K39/0208 ,  A61K39/12 ,  A61K39/295 ,  A61K39/39 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C07K14/30 ,  C12N1/36 ,  C12N2750/10021 ,  C12N2750/10034 ,  C12N2750/10063 ,  C12N2770/10034

Abstract: This invention provides an immunogenic composition including the supernatant of a Mycoplasma hyopneumoniae (M.hyo) culture, wherein the supernatant of the M.hyo culture has been separated from insoluble cellular material by centrifugation, filtration, or precipitation and is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

公开(公告)号：US09650601B2

公开(公告)日：2017-05-16

申请号：US14712454

申请日：2015-05-14

Applicant: Zoetis Services LLC

Inventor： Gregory P. Nitzel ,  Jeffrey E. Galvin ,  John Keith Garrett ,  James R. Kulawik, II ,  Tracy L. Ricker ,  Megan Marie Smutzer

IPC: C12N1/36 ,  A61K39/02 ,  A61K39/12 ,  A61K39/295 ,  A61K39/00

CPC classification number: C12N1/36 ,  A61K39/0208 ,  A61K39/0241 ,  A61K39/12 ,  A61K39/295 ,  A61K2039/521 ,  A61K2039/5252 ,  A61K2039/552 ,  A61K2039/55566 ,  A61K2039/70 ,  C12N2750/10034 ,  C12N2770/10034

Abstract: This invention provides a trivalent immunogenic composition including a soluble portion of a Mycoplasma hyopneumoniae (M.hyo) whole cell preparation; a porcine circovirus type 2 (PCV2) antigen; and a PRRS virus antigen, wherein the soluble portion of the M.hyo preparation is substantially free of both (i) IgG and (ii) immunocomplexes comprised of antigen bound to immunoglobulin.

公开(公告)号：US09603917B2

公开(公告)日：2017-03-28

申请号：US14833454

申请日：2015-08-24

Applicant: GalenBio, Inc.

Inventor： Susan Szathmary ,  Laszlo Stipkovits

IPC: A61K39/385 ,  A61K39/02 ,  C07K14/30 ,  A61K47/48 ,  A61K39/00

CPC classification number: A61K39/0241 ,  A61K39/385 ,  A61K47/61 ,  A61K47/6927 ,  A61K2039/552 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/55583 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/6087 ,  C07K14/30

Abstract: This invention provides a microparticle carrier system comprising of one or more proteins, peptides, nucleic acids, carbohydrates, lipids or other bioactive substances with or without targeting molecules attached. In addition, the invention also provides immune modulatory compositions and methods of eliciting protective immune responses both in uninfected and infected hosts as well as the induction of immune tolerance.

公开(公告)号：US20170081372A1

公开(公告)日：2017-03-23

申请号：US15017486

申请日：2016-02-05

Applicant: MERIAL INC.

Inventor： Laurent Bernard Fischer ,  Nicolas Pierre Yves Carboulec ,  Fabien Lux

IPC: C07K14/44 ,  C12N9/50 ,  A61K39/008 ,  C12N9/10

CPC classification number: C07K14/245 ,  A23L3/0155 ,  A61K39/008 ,  A61K39/0225 ,  A61K39/0241 ,  A61K39/099 ,  A61K2039/552 ,  A61L2/0011 ,  C07K14/44 ,  C07K2319/00 ,  C07K2319/35 ,  C07K2319/40 ,  C12N5/0031 ,  C12N9/1007 ,  C12N9/50 ,  C12N9/52 ,  C12P21/02 ,  C12Y201/01041 ,  C12Y304/22

Abstract: The present invention encompasses vaccines or compositions comprising the chimeric KSAC protein that possesses immunogenic and protective properties, and methods of use including administering to an animal the antigenic KSAC protein thereof to protect animals. The invention also encompasses methods for making and producing the soluble, disaggregated, refolded or active proteins from inclusion bodies produced from prokaryotes or eukaryotes.

公开(公告)号：US09593150B2

公开(公告)日：2017-03-14

申请号：US14415307

申请日：2013-07-16

Applicant: THE SCRIPPS RESEARCH INSTITUTE ,  Rajesh Grover ,  Richard Lerner ,  Ian Wilson ,  Xueyong Zhu

Inventor： Rajesh Grover ,  Richard Lerner ,  Ian Wilson ,  Xueyong Zhu

IPC: G01N33/53 ,  G01N33/567 ,  G01N33/569 ,  C07K14/30 ,  A61K39/04 ,  C07K14/35 ,  C07K16/12 ,  C07K16/30 ,  A61K39/02

CPC classification number: C07K14/30 ,  A61K39/0241 ,  A61K39/04 ,  C07K14/35 ,  C07K16/1253 ,  C07K16/3061 ,  C07K2317/10 ,  C07K2317/55

Abstract: Provided herein methods of alleviating the symptoms of multiple myeloma in a patient or subject in need thereof, methods of treating multiple myeloma in a patient or subject, and methods of preventing development of multiple myeloma in a patient at risk thereof, such as a patient with monoclonal gammopathy of undetermined significance (MGUS), which methods include administering an agent effective to treat a Mycoplasma infection. The invention also relates to a new class of antigen, MG281 protein {also referenced as Protein M), that binds to various immunoglobulins with high affinity, and their uses in purifying immunoglobulins. The invention additionally relates to using MG281 protein and analog or derivative molecules for treating autoimmune diseases. Further provided are antigens and antibodies for use in the disclosed methods, and the identification of molecules that bind to MG281 protein.

Abstract translation: 本文提供减轻患者或受试者的多发性骨髓瘤症状的方法，治疗患者或受试者中的多发性骨髓瘤的方法，以及在患有风险的患者中预防多发性骨髓瘤发展的方法，例如具有 具有未确定意义的单克隆丙种球蛋白病（MGUS），该方法包括施用有效治疗支原体感染的药剂。 本发明还涉及以高亲和力结合各种免疫球蛋白的新一类抗原MG281蛋白（也称为蛋白M），以及它们在纯化免疫球蛋白中的用途。 本发明还涉及使用MG281蛋白和类似物或衍生物分子来治疗自身免疫性疾病。 还提供了用于所公开的方法中的抗原和抗体，以及鉴定结合MG281蛋白的分子。